Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note published on Monday,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

Several other research analysts have also weighed in on the company. TD Cowen reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Finally, Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Stock Performance

NASDAQ:HUMA opened at $4.39 on Monday. The company’s 50-day moving average is $4.66 and its two-hundred day moving average is $5.69. The firm has a market capitalization of $552.52 million, a price-to-earnings ratio of -3.28 and a beta of 1.32. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. Humacyte has a 1-year low of $2.48 and a 1-year high of $9.97.

Insider Activity

In related news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the transaction, the chief executive officer now owns 1,730,884 shares in the company, valued at $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,500,000 shares of company stock worth $6,606,799. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HUMA. State Street Corp lifted its stake in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after purchasing an additional 1,895,529 shares during the last quarter. Geode Capital Management LLC raised its holdings in Humacyte by 9.6% during the third quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after purchasing an additional 179,120 shares in the last quarter. Millennium Management LLC lifted its position in shares of Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after buying an additional 1,334,641 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Humacyte by 10.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock valued at $3,924,000 after buying an additional 66,946 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.